Drug Profile
Research programme: coagulation factor modulators - Aronora
Alternative Names: AB-012; AXIMABLatest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Oregon Health & Science University; Washington University
- Developer Aronora; Oregon Health & Science University; Washington University
- Class Enzymes; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Factor IX inhibitors; Factor XI inhibitors; Factor XIIa inhibitors; Thrombin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Sepsis; Venous thrombosis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Sepsis in USA (Parenteral)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Venous-thrombosis in USA (Parenteral)